01 Pharmaron Beijing Co.Ltd(300759) (Beijing) new drug Technology Co., Ltd. on the release cycle of this report
This report is the third annual environmental, social and Governance (ESG) report issued by Pharmaron Beijing Co.Ltd(300759) (Beijing) new drug Technology Co., Ltd. the time range of this report is from January 1, 2021 to December 31, 2021, and some contents may exceed the above time range.
Scope of reporting organization
This report covers the relevant data of Pharmaron Beijing Co.Ltd(300759) (Beijing) new drug Technology Co., Ltd. and its important subsidiaries and branches. For ease of expression, “KANGLONG Huacheng”, “the group”, “the company” and “we” are also used in this report. Report preparation principles
This report is prepared in accordance with the guidelines on environmental, social and governance reporting issued by the stock exchange of Hong Kong Limited (“SEHK”), with reference to the guidelines on social responsibility of listed companies on the Shenzhen Stock Exchange issued by the Shenzhen Stock Exchange, the GRI standards for sustainable development reporting issued by the global sustainable development standards committee and the key indicators in MSCI ESG rating.
ESG reporting principles
Importance quantification balance consistency
This report follows the principle of quantitative key performance in the important report of the stock exchange. This report presents the data disclosed in this report in an impartial manner. The statistical standards and methods of indicators in the report and the statistical methods of the group’s tables during the reporting period maintain the same disclosure of the working assumptions and / or calculation tools of the board of directors and ESG, so as to avoid possible inappropriateness.
The group considers ESG matters, benefits and the source of conversion factors, which affect the decision-making of the report readers
The selection, omission or presentation of judgment shall be noted in each data sheet of the report
The issue identification process and substantive issues will be described. Report format.
Issue matrix, specific compliance
See the corresponding part later for details.
Name Description
Interpretation of abbreviation in the report
Group, the group, our company and its subsidiaries
Pharmaron Beijing Co.Ltd(300759) , the company, the company Pharmaron Beijing Co.Ltd(300759) (Beijing) new drug Technology Co., Ltd
KANGLONG Xi’an Pharmaron Beijing Co.Ltd(300759) (Xi’an) new drug Technology Co., Ltd
KANGLONG Tianjin Pharmaron Beijing Co.Ltd(300759) (Tianjin) pharmaceutical preparation technology Co., Ltd
KANGLONG Ningbo technology Pharmaron Beijing Co.Ltd(300759) (Ningbo) Technology Development Co., Ltd
KANGLONG Shanghai Pharmaron Beijing Co.Ltd(300759) (Shanghai) new drug Technology Co., Ltd
KANGLONG clinical Pharmaron Beijing Co.Ltd(300759) (Chengdu) Clinical Research Service Co., Ltd
Pharmaron UK Pharmaron UK Limited
Pharmaron Biologics UK Pharmaron Biologics (UK) Ltd
Description of monetary unit unless otherwise specified, the amounts disclosed in the report are measured in RMB.
03 Pharmaron Beijing Co.Ltd(300759) (Beijing) ESG governance statement of the board of directors of new drug Technology Co., Ltd
The board of directors of the group attaches great importance to sustainable development and ESG management,
Built a complete structure, clear hierarchy, clear rights and responsibilities and operation
An efficient three-level ESG governance structure has established an effective
ESG management mechanism. The board of directors attaches great importance to matters related to the group’s business
Identify, evaluate and manage ESG related matters, and determine
Listen to the reports of relevant committees and management. The board of directors annually
Specially listen to and review the group’s environmental, social and governance report,
And check the implementation progress against the set ESG related objectives. war
The ESG Executive Committee under the strategy committee is responsible for identifying
ESG major issues and risks, formulate ESG objectives and
Update ESG related management system and report to the strategy committee.
This report discloses the details of the group’s ESG work in 2021
The progress and effectiveness shall be reviewed and approved by the board of directors before disclosure.
The board of directors and all directors of the group guarantee that the information contained in this report is not accurate
There are false records, misleading statements or major omissions, and
The authenticity, accuracy and completeness of its contents shall be borne by individual and
joint responsibility.
2021 environmental, social and Governance Report 0405 Pharmaron Beijing Co.Ltd(300759) (Beijing) speech by the chairman of new drug Technology Co., Ltd
2021 is a challenging year, and the global pandemic of covid-19 epidemic still affects all parts of the world. 2021 is a year worth looking forward to
Science and technology have pointed out the direction for human beings to fight the epidemic. The world has entered the stage of intelligent epidemic prevention, vaccines have been vaccinated, and covid-19 therapeutic drugs have been put on the market one after another.
In this critical year when opportunities and challenges coexist, we adhere to the principle of “helping partners develop new drugs for human health with the highest level of R & D services”
Kang contributed Pharmaron Beijing Co.Ltd(300759) wisdom.
”Strengthen the core competitiveness of the whole process and integrated service platform. Through comprehensive drug research and development
Develop services, help customers’ R & D projects, shorten R & D time, reduce R & D costs, and contribute Pharmaron Beijing Co.Ltd(300759) wisdom to human health.
We are well aware that good ESG management is crucial to the sustainable development of the group. We constantly improve the compliance management system and focus on the core points of anti-corruption and anti-corruption, which is the basic guarantee for ESG work. We have made unremitting efforts to identify and prevent compliance risks, improve compliance reporting and investigation, continue to improve ESG governance system, integrate ESG governance into corporate governance and economic mechanism, and escort our sustainable development.
And continuously strengthen the ESG management system through improving policies and systems
We know that the development of enterprises is inseparable from the development of society. As corporate citizens, we carry out special actions and strengthen transparent operation to promote ESG management ability
We should assume our due responsibilities and obligations. In maintaining its own sustainable and continuous improvement.
On the basis of development, we will undertake to build a three-level ESG of “governance layer – management layer – executive layer” from a deeper, greater and wider field, govern the corporate citizenship structure of society, environment, employees, customers and supply chain, and clarify the work responsibilities and responsibilities of personnel at all levels, departments and positions.
Form an ESG with complete structure, clear hierarchy, clear rights and responsibilities and efficient operation
We are committed to providing customers with high-quality and high-value services and novel governance structure, and promoting the implementation of the group’s ESG work from concept to practice.
Establish a complete quality assurance system, and strictly manage the whole process and aspects of ESG management from customer acceptance, our release and implementation of the measures for the management of environmental, social and corporate governance, raw material procurement, R & D service implementation, quality inspection, R & D product delivery and the environmental, social and corporate governance information management manual; Maintain information security and provide institutional guarantee for the improvement of processing ability and level. Formulate a comprehensive information security management strategy to ensure the confidentiality, integrity and availability of information assets; Build “company management – system policy – legal documents – we attach importance to and always pay attention to the interaction with stakeholders,
The five level intellectual property protection system of “employee training – technical support” and the evaluation and analysis of ESG topics through questionnaire survey, interview and communication
Strong intellectual property protection.
And take it as responsibility management, strategic decision-making and information disclosure
An important basis for the strategy, actively respond to the demands of stakeholders and improve our management in accordance with ethics in all research activities and experiments. De, in the process of preclinical animal experiments, formulated and implemented a number of internal control measures
Environmental, social and Governance Report 202106
Manage policies and operation specifications, try to meet the physiological welfare of experimental animals, and the research and development of new environmental drugs is related to human health and well-being. In the new year, I
Environmental welfare, health welfare, psychological welfare and behavioral welfare; We provide professionals who will continue to pay attention to safety, fear science and fear life,
Clinical research services of the industry, and carry out the whole process of clinical trial projects to the society, environment, investors / shareholders, employees, customers and suppliers
Risk control, give priority to the rights and interests and safety of subjects in the process, and guarantee the chain and other stakeholders to bear the responsibility. Practice our leadership in ESG
Quality of clinical trials. The commitment of the domain to create a greener, healthy and sunny Pharmaron Beijing Co.Ltd(300759) ,
Take practical actions to realize the sustainable development of economy, environment and society
We adhere to the principle of “honesty and trustworthiness, mutual benefit and win-win” and cooperate with suppliers
Contribute.
Cooperation, focusing on integrity management, business information security, supply chain labor rights, Dr. Lou Bailiang
Core issues such as environmental protection of Yihe supply chain, prevention and control of supply chain environment and Pharmaron Beijing Co.Ltd(300759) (Beijing) new drug Technology Co., Ltd
Social risks; Carry out sunshine procurement and strive to create a fair competition for suppliers
Fight for the environment.
We regard employees as the core competitiveness to achieve sustainable development. We actively build a talent empowerment platform for joint creation and sharing, support and encourage employees to maintain their desire and sense of crisis for new technologies, new methods and new needs, maintain their resilience in the face of difficulties, maintain a positive attitude of trying our best to solve problems, create an inclusive and equal working environment, build a “warm” employee home, and promote the common development of employees and enterprises.
Along the way, “green” and “low carbon” have always been one of our keywords. In 2016, we formulated and achieved the five-year sustainable development goal. Compared with 2016, the water consumption and energy consumption of 10000 yuan output value in 2020 will be reduced by 25% and 20% respectively, and good results have been achieved in energy conservation and emission reduction. two hundred and two
